Details of the Drug

General Information of Drug (ID: DMGV8QU)

Drug Name

Etravirine

Synonyms

Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Approved	[1]
------------------------------------------------------------------------------------

ATC Code

J05AG04: Etravirine

J05AG: Non-nucleoside reverse transcriptase inhibitors

J05A: DIRECT ACTING ANTIVIRALS

J05: ANTIVIRALS FOR SYSTEMIC USE

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

435.3

Logarithm of the Partition Coefficient (xlogp)

4.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination: 0% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 9.05 - 41 hours [3]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.5638 micromolar/kg/day [4]

Chemical Identifiers

Formula: C20H15BrN6O
IUPAC Name: 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
Canonical SMILES: CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
InChI: InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
InChIKey: PYGWGZALEOIKDF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 193962
ChEBI ID: CHEBI:63589
CAS Number: 269055-15-4
UNII: 0C50HW4FO1
DrugBank ID: DB06414
TTD ID: D0BP9C
VARIDT ID: DR00597
INTEDE ID: DR0671
ACDINA ID: D00259

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Modulator	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Etravirine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
MK-1439	DM215WE	Major	Increased metabolism of Etravirine caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Etravirine caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Etravirine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Dolutegravir	DMCZGRE	Major	Increased metabolism of Etravirine caused by Dolutegravir mediated induction of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Etravirine caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
-----------

Coadministration of a Drug Treating the Disease Different from Etravirine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Etravirine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Etravirine caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[13]
Arn-509	DMT81LZ	Major	Increased metabolism of Etravirine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Gilteritinib	DMTI0ZO	Moderate	Increased metabolism of Etravirine caused by Gilteritinib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Major	Increased metabolism of Etravirine caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[15]
Ivabradine	DM0L594	Moderate	Increased metabolism of Etravirine caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[16]
Bedaquiline	DM3906J	Major	Increased metabolism of Etravirine caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[16]
Troleandomycin	DMUZNIG	Moderate	Increased metabolism of Etravirine caused by Troleandomycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Erdafitinib	DMI782S	Major	Increased metabolism of Etravirine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[17]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Etravirine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[12]
HKI-272	DM6QOVN	Major	Increased metabolism of Etravirine caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[11]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Etravirine caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Etravirine caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Etravirine caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[11]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Etravirine caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Cabazitaxel	DMPAZHC	Moderate	Increased metabolism of Etravirine caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Bosutinib	DMTI8YE	Major	Increased metabolism of Etravirine caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Macitentan	DMP79A1	Moderate	Increased metabolism of Etravirine caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[23]
PF-04449913	DMSB068	Major	Increased metabolism of Etravirine caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[24]
Ulipristal	DMBNI20	Moderate	Increased metabolism of Etravirine caused by Ulipristal mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[16]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Etravirine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[12]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Etravirine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[25]
Vilazodone	DM4LECQ	Moderate	Increased metabolism of Etravirine caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[26]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Etravirine caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[27]
OPC-34712	DMHG57U	Moderate	Increased metabolism of Etravirine caused by OPC-34712 mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Etravirine caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Etravirine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Etravirine caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[28]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Etravirine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[29]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Etravirine caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[30]
Ripretinib	DM958QB	Moderate	Increased metabolism of Etravirine caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[11]
Avapritinib	DMK2GZX	Major	Increased metabolism of Etravirine caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[16]
Boceprevir	DMBSHMF	Moderate	Increased metabolism of Etravirine caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[12]
Daclatasvir	DMSFK9V	Major	Increased metabolism of Etravirine caused by Daclatasvir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[11]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Etravirine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[31]
Levamlodipine	DM92S6N	Moderate	Increased metabolism of Etravirine caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Etravirine due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[32]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Etravirine caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[33]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Etravirine caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[34]
Naloxegol	DML0B41	Moderate	Increased metabolism of Etravirine caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[35]
Pemigatinib	DM819JF	Major	Increased metabolism of Etravirine caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[16]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Etravirine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Brigatinib	DM7W94S	Major	Increased metabolism of Etravirine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[11]
Ceritinib	DMB920Z	Moderate	Increased metabolism of Etravirine caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Etravirine caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
PF-06463922	DMKM7EW	Major	Increased metabolism of Etravirine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[37]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Etravirine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[38]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Etravirine caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Capmatinib	DMYCXKL	Major	Increased metabolism of Etravirine caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[40]
Artemether	DM48QOT	Major	Increased metabolism of Etravirine caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[11]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Etravirine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[12]
GDC-0199	DMH0QKA	Major	Increased metabolism of Etravirine caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[41]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Etravirine caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[42]
Ibrutinib	DMHZCPO	Moderate	Increased metabolism of Etravirine caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[43]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Etravirine caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[11]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Etravirine caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[12]
Selumetinib	DMC7W6R	Major	Increased metabolism of Etravirine caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[44]
LGX818	DMNQXV8	Major	Increased metabolism of Etravirine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[45]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Etravirine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[12]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Etravirine caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[46]
Rimegepant	DMHOAUG	Major	Increased metabolism of Etravirine caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[47]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Etravirine caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[48]
Siponimod	DM2R86O	Major	Increased metabolism of Etravirine caused by Siponimod mediated induction of CYP450 enzyme.	Multiple sclerosis [8A40]	[11]
Deflazacort	DMV0RNS	Major	Increased metabolism of Etravirine caused by Deflazacort mediated induction of CYP450 enzyme.	Muscular dystrophy [8C70]	[16]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Etravirine caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Etravirine caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[49]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Etravirine caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[16]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Etravirine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[12]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Etravirine caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[16]
Entrectinib	DMMPTLH	Major	Increased metabolism of Etravirine caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[50]
S-297995	DM26IH8	Moderate	Increased metabolism of Etravirine caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[16]
Olaparib	DM8QB1D	Major	Increased metabolism of Etravirine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[11]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Etravirine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[12]
Istradefylline	DM20VSK	Moderate	Increased metabolism of Etravirine caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[12]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Etravirine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[51]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Etravirine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[12]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Etravirine caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[52]
Lefamulin	DME6G97	Major	Increased metabolism of Etravirine caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[53]
Lonafarnib	DMGM2Z6	Major	Increased metabolism of Etravirine caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[54]
Enzalutamide	DMGL19D	Major	Increased metabolism of Etravirine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Etravirine caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[55]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Etravirine caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[56]
Axitinib	DMGVH6N	Major	Increased metabolism of Etravirine caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[57]
Upadacitinib	DM32B5U	Moderate	Increased metabolism of Etravirine caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[58]
Tofacitinib	DMBS370	Moderate	Increased metabolism of Etravirine caused by Tofacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[11]
Voxelotor	DMCS6M5	Major	Increased metabolism of Etravirine caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[59]
LDE225	DMM9F25	Major	Increased metabolism of Etravirine caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[60]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Etravirine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Etravirine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
LEE011	DMMX75K	Moderate	Increased metabolism of Etravirine caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Etravirine caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[12]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Etravirine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[61]
Apixaban	DM89JLN	Moderate	Increased metabolism of Etravirine caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[62]
Brilinta	DMBR01X	Moderate	Increased metabolism of Etravirine caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[15]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Etravirine caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[63]
Linagliptin	DMWFJTR	Moderate	Increased metabolism of Etravirine caused by Linagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[64]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Etravirine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[12]
-----------


⏷ Show the Full List of 97 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Etravirine 100 mg tablet	100 mg	Oral Tablet	Oral
Etravirine 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
6	Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4.
7	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
8	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
9	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
10	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
11	Cerner Multum, Inc. "Australian Product Information.".
12	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
13	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
14	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
15	Canadian Pharmacists Association.
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
18	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
19	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
20	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
21	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
22	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23	Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
24	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
26	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
27	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
28	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
29	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
30	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
31	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
32	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
33	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
34	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
35	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
37	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
40	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
42	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
44	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
46	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
47	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
48	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
50	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
51	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
52	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
53	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
54	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
55	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
56	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
57	Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
58	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
59	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
60	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
61	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
62	Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
63	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
64	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.